According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion independence compared with 15.0% of patients treated with placebo. Respondents ...

Luspatercept showed similar efficacy and safety in real-world settings as observed in the MEDALIST trial for LR-MDS patients post-ESA failure. Transfusion independence was achieved in 44.3% of ...

Luspatercept shows higher efficacy than ESAs in increasing hemoglobin levels and sustaining improvement in LR-MDS patients. Patients treated with luspatercept achieve faster and more sustained red ...

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...

Please provide your email address to receive an email when new articles are posted on . Individuals exposed to Agent Orange exhibited significantly higher risk for MDS. Exposure appeared associated ...